Herbs in hemato-oncological care: An evidence-based review of data on efficacy, safety, and drug interactions

Leukemia and Lymphoma

Volumn 51, Issue 8, 2010, Pages 1414-1423

  Ben Arye, Eran ^a,b   Attias, Samuel ^c   Tadmor, Tamar ^d   Schiff, Elad ^c,d  

^a CLALIT HEALTH SERVICES   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c UNIVERSITY OF HAIFA   (Israel)

^d BNAI ZION MEDICAL CENTER   (Israel)

Author keywords

complementary alternative medicine; doctorpatient communication; hematologyoncology; Herbal medicine; integrative medicine

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DACARBAZINE; ECHINACEA EXTRACT; ETOPOSIDE; GARLIC EXTRACT; GINGER EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLYCOPROTEIN P; GRAPE SEED EXTRACT; HYPERICUM PERFORATUM EXTRACT; IMATINIB; KAVA; NAVELBINE; TENIPOSIDE; UNINDEXED DRUG; VALERIAN; VINBLASTINE; VINCRISTINE; VINDESINE;

CANCER PATIENT; CELL CULTURE; CELL LINE; CHINESE HERB; DRUG EFFICACY; DRUG SAFETY; ECHINACEA; GARLIC; GINKGO BILOBA; GINSENG; HEMATOLOGIC MALIGNANCY; HERBAL MEDICINE; HUMAN; HYPERICUM PERFORATUM; LEUKEMIA; LYMPHOMA; MEDICINE; MYELOMA; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; QUALITY CONTROL; RESEARCH; REVIEW; SPICE; TEA; TRADITIONAL MEDICINE; VISCUM ALBUM; WELLBEING;

CLINICAL TRIALS AS TOPIC; HEMATOLOGIC NEOPLASMS; HERB-DRUG INTERACTIONS; HUMANS; PHYTOTHERAPY; PLANTS, MEDICINAL; SAFETY; TREATMENT OUTCOME;

EID: 77955446495     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.487622     Document Type: Review

References (94)

1. Molassiotis A, Margulies A, Fernandez-Ortega P, et al. Complementary and alternative medicine use in patients with haematological malignancies in Europe. Complement Ther Clin Pract 2005;11:105-110.
2. Hensel M, Zoz M, Ho AD. Complementary and alternative medicine in patients with chronic lymphocytic leukemia. Support Care Cancer 2009;17:47-52.
3. Habermann TM, Thompson CA, LaPlant BR, et al. Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study. Am J Hematol 2009;84: 795-798.
4. Gupta M, Shafiq N, Kumari S, Pandhi P. Patterns and perceptions of complementary and alternative medicine (CAM) among leukaemia patients visiting haematology clinic of a north Indian tertiary care hospital. Pharmacoepidemiol Drug Saf 2002;11:671-676.
5. Lourenco MT, Walsh A, Boon H, et al. Superstition but not distrust in the medical system predicts the use of complementary and alternative medicine in a group of patients with acute leukemia. Leuk Lymphoma 2008;49:339-341.
6. Cassileth BR, Vickers AJ. High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care. J Clin Oncol 2005;23: 2590-2592.
7. Deng GE, Cassileth BR, Cohen L, et al. Society for Integrative Oncology Executive Committee, Abrams D, Rosenthal D, Sagar S, Tripathy D. Integrative oncology practice guidelines. J Soc Integr Oncol 2007;5:65-84.
8. Frenkel M, Ben-Arye E. Communicating with patients about the use of complementary and integrative medicine in cancer care. In: Cohen L, Markman M, editors. Integrative oncology: incorporating complementary medicine into conventional care. Totowa, NJ: Humana Press; 2008. pp. 33-46.
9. Atwood KC 4th. Patients have a 'CAM' knowledge gap-but who will fill it? Am J Hematol 2009;84:788-789.
10. Verhoef MJ, Boon HS, Page SA. Talking to cancer patients about complementary therapies: is it the physician's responsibility? Curr Oncol 2008;15:88-93.
11. Ben-Arye E, Schiff E, Golan O. Ethical issues in integrative oncology. Hematol Oncol Clin North Am 2008;22:737-753.
12. Oh WK, Kantoff PW, Weinberg V, et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004; 22:3705-3712.
13. Ikezoe T, Chen S, Saito T, et al. PC-SPES decreases proliferation and induces differentiation and apoptosis of human acute myeloid leukemia cells. Int J Oncol 2003;23: 1203-1211.
14. Shabbir M, Love J, Montgomery B. Phase I trial of PC-Spes2 in advanced hormone refractory prostate cancer. Oncol Rep 2008;19:831-835.
15. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev 2002;(2):CD003383.
16. Clouatre DL. Kava kava: examining new reports of toxicity. Toxicol Lett 2004;150:85-96.
17. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-2503.
18. Weiss J, Sauer A, Frank A, Unger M. Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro. Drug Metab Dispos 2005;33: 1580-1583.
19. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008;(4): CD000448.
20. Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004;24:1508-1514.
21. Engdal S, Klepp O, Nilsen OG. Identification and exploration of herb-drug combinations used by cancer patients. Integr Cancer Ther 2009;8:29-36.
22. Available from: http://dietarysupplements.nlm.nih.gov/dietary/. Accessed 02/24/2010.
23. Available from: http://www.nlm.nih.gov/medlineplus/druginformation. html. Accessed 02/24/2010.
24. Available from: http://www.naturaldatabase.com. Accessed 02/24/2010.
25. Khil LY, Kim W, Lyu S, Park WB, Yoon JW, Jun HS. Mechanisms involved in Korean mistletoe lectin-induced apoptosis of cancer cells. World J Gastroenterol 2007;13: 2811-2818.
26. Valentiner U, Pfüller U, Baum C, Schumacher U. The cytotoxic effect of mistletoe lectins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro. Toxicology 2002;171:187-199.
27. Urech K, Buessing A, Thalmann G, Schaefermeyer H, Heusser P. Antiproliferative effects of mistletoe (Viscum album L.) extract in urinary bladder carcinoma cell lines. Anticancer Res 2006;26:3049-3055.
28. Lee SJ, Son YO, Kim H, et al. Suppressive effect of a standardized mistletoe extract on the expression of activatory NK receptors and function of human NK cells. J Clin Immunol 2007;27:477-485.
29. Kovacs E. The in vitro effect of Viscum album (VA) extract on DNA repair of peripheral blood mononuclear cells (PBMC) in cancer patients. Phytother Res 2002;16:143-147.
30. Elluru SR, Van Huyen JP, Delignat S, et al. Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity. Anticancer Res 2009;29:2945-2950.
31. Elluru SR, van Huyen JP, Delignat S, et al. Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer 2008; 8:161.
32. Huber R, Rostock M, Goedl R, et al. Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo controlled randomized study in healthy subjects. Eur J Med Res 2005;10:411-418.
33. Kienle GS, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 2007;12:103-119.
34. Enesel MB, Acalovschi I, Grosu V, et al. Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients. Anticancer Res 2005;25:4583-4590.
35. Bock PR, Friedel WE, Hanisch J, Karasmann M, Schneider B. Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittelforschung 2004;54:456-466.
36. Klopp R, Schmidt W, Werner E, Werner M, Niemer W, Beuth J. Influence of complementary Viscum album (Iscador) administration on microcirculation and immune system of ear, nose and throat carcinoma patients treated with radiation and chemotherapy. Anticancer Res 2005;25: 601-610.
37. Ziegler R, Grossarth-Maticek R. Individual patient data metaanalysis of survival and psychosomatic self-regulation from published prospective controlled cohort studies for long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). Evid Based Complement Alternat Med 2008 Apr 11. [Epub ahead of print].
38. Elsässer-Beile U, Leiber C, Wetterauer U, et al. Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer. Anticancer Res 2005;25:4733-4736.
39. Seifert G, Jesse P, Laengler A, et al. Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. Cancer Lett 2008;264: 218-228.
40. Kovacs E, Link S, Toffol-Schmidt U. Comparison of Viscum album QuFrF extract with vincristine in an in vitro model of human B cell lymphoma WSU-1. Arzneimittelforschung 2008;58:592-597.
41. Engdal S, Nilsen OG. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res 2009;23:906-912.
42. Dresser GK, Spence JD, Bailey DG. Pharmacokineticpharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
43. Han DH, Jeong JH, Kim JH. Anti-proliferative and apoptosis induction activity of green tea polyphenols on human promyelocytic leukemia HL-60 cells. Anticancer Res 2009;29:1417-1421.
44. Shammas MA, Neri P, Koley H, et al. Specific killing of multiple myeloma cells by (7)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 2006;108:2804-2810.
45. Golden EB, Lam PY, Kardosh A, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009;113:5927-5937.
46. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3- gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004;104:788-794.
47. Shanafelt TD, Lee YK, Call TG, et al. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 2006;30:707-712.
48. Shanafelt TD, Call TG, Zent CS, et al. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 2009; 27:3808-3814.
49. Kuo YC, Yu CL, Liu CY, et al. Kaohsiung Leukemia Research Group. A population-based, case-control study of green tea consumption and leukemia risk in southwestern Taiwan. Cancer Causes Control 2009;20:57-65.
50. Krishnaswamy K. Traditional Indian spices and their health significance. Asia Pac J Clin Nutr 2008;17:265-268.
51. Levey M. The medical formulary or the aqr-ab-adh-in of al- Kind-i. Madison, WI: The University of Wisconsin Press; 1966.
52. Lev-Ari S, Strier L, Kazanov D, et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 2005;11:6738-6744.
53. Lev-Ari S, Vexler A, Starr A, et al. Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines. Cancer Invest 2007;25:411-418.
54. Ghosh AK, Kay NE, Secreto CR, Shanafelt TD. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res 2009;15:1250-1258.
55. Park J, Ayyappan V, Bae EK, et al. Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol Oncol 2008;2: 317-326.
56. Tavakkol-Afshari J, Brook A, Mousavi SH. Study of cytotoxic and apoptogenic properties of saffron extract in human cancer cell lines. Food Chem Toxicol 2008;46:3443-3447.
57. Premkumar K, Thirunavukkarasu C, Abraham SK, Santhiya ST, Ramesh A. Protective effect of saffron (Crocus sativus L.) aqueous extract against genetic damage induced by anti-tumor agents in mice. Hum Exp Toxicol 2006;25:79-84.
58. Tarantilis PA, Morjani H, Polissiou M, Manfait M. Inhibition of growth and induction of differentiation of promyelocytic leukemia (HL-60) by carotenoids from Crocus sativus L. Anticancer Res 1994;14:1913-1918.
59. Levine ME, Gillis MG, Koch SY, et al. Protein and ginger for the treatment of chemotherapy-induced delayed nausea. J Altern Complement Med 2008;14:545-551.
60. Zick SM, Ruffin MT, Lee J, et al. Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer 2009;17:563-572.
61. Wang CC, Chen LG, Lee LT, Yang LL. Effects of 6-gingerol, an antioxidant from ginger, on inducing apoptosis in human leukemic HL-60 cells. In Vivo 2003;17:641-645.
62. Kaileh M, Berghe WV, Boone E, Essawi T, Haegeman G. Screening of indigenous Palestinian medicinal plants for potential anti-inflammatory and cytotoxic activity. J Ethnopharmacol 2007;113:510-516.
63. Hibasami H, Yamada Y, Moteki H, et al. Sesquiterpenes (costunolide and zaluzanin D) isolated from laurel (Laurus nobilis L.) induce cell death and morphological change indicative of apoptotic chromatin condensation in leukemia HL-60 cells. Int J Mol Med 2003;12:147-151.
64. Dy GK, Bekele L, Hanson LJ, et al. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. J Clin Oncol 2004;22:4810-4815.
65. Melchart D, Clemm C, Weber B, et al. Polysaccharides isolated from Echinacea purpurea herba cell cultures to counteract undesired effects of chemotherapy-a pilot study. Phytother Res 2002;16:138-142.
66. Currier NL, Miller SC. Echinacea purpurea and melatonin augment natural-killer cells in leukemic mice and prolong life span. J Altern Complement Med 2001;7:241-251.
67. Hayashi I, Ohotsuki M, Suzuki I, Watanabe T. Effects of oral administration of Echinacea purpurea (American herb) on incidence of spontaneous leukemia caused by recombinant leukemia viruses in AKR/J mice. Nihon Rinsho Meneki Gakkai Kaishi 2001;24:10-20.
68. Gonzales GF, Valerio LG Jr. Medicinal plants from Peru: a review of plants as potential agents against cancer. Anticancer Agents Med Chem 2006;6:429-444.
69. Bacher N, Tiefenthaler M, Sturm S, Stuppner H, Ausserlechner MJ, Kofler R, Konwalinka G. Oxindole alkaloids from Uncaria tomentosa induce apoptosis in proliferating, G0/G1-arrested and bcl-2-expressing acute lymphoblastic leukaemia cells. Br J Haematol 2006;132: 615-622.
70. Cheng AC, Jian CB, Huang YT, Lai CS, Hsu PC, Pan MH. Induction of apoptosis by Uncaria tomentosa through reactive oxygen species production, cytochrome c release, and caspases activation in human leukemia cells. Food Chem Toxicol 2007;45:2206-2218.
71. De Martino L, D'Arena G, Minervini MM, et al. Verbena officinalis essential oil and its component citral as apoptoticinducing agent in chronic lymphocytic leukemia. Int J Immunopathol Pharmacol 2009;22:1097-1104.
72. Dudai N, Weinstein Y, Krup M, Rabinski T, Ofir R. Citral is a new inducer of caspase-3 in tumor cell lines. Planta Med 2005;71:484-488.
73. Jesse P, Mottke G, Eberle J, Seifert G, Henze G, Prokop A. Apoptosis-inducing activity of Helleborus niger in ALL and AML. Pediatr Blood Cancer 2009;52:464-469.
74. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004;24:2783-2840.
75. Li T, Wang W, Chen H, Li T, Ye L. Evaluation of antileukemia effect of resveratrol by modulating SATA3 signaling. Int Immunopharmacol 2010;10:18-25.
76. Roman V, Billard C, Kern C, et al. Analysis of resveratrolinduced apoptosis in human B-cell chronic leukaemia. Br J Haematol 2002;117:842-851.
77. Faber AC, Chiles TC. Resveratrol induces apoptosis in transformed follicular lymphoma OCI-LY8 cells: evidence for a novel mechanism involving inhibition of BCL6 signaling. Int J Oncol 2006;29:1561-1566.
78. Bhardwaj A, Sethi G, Vadhan-Raj S, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007;109:2293-2302.
79. Ben-Arye E, Lev E, Keshet Y, Schiff E. Integration of herbal medicine in primary care in Israel: a Jewish-Arab crosscultural perspective. Evid Based Complement Alternat Med 2009 Oct 28. [Epub ahead of print].
80. Xiao Z, Wang Y, Lu L, et al. Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro. Leuk Res 2006;30:54-59.
81. Yuki F, Kawaguchi T, Hazemoto K, Asou N. Preventive effects of oren-gedoku-to on mucositis caused by anticancer agents in patients with acute leukemia. Gan To Kagaku Ryoho 2003;30:1303-1307.
82. Wei YF, Wang SY, Ren LL. Efficacy of shenqi fuzheng injection combined with chemotherapy in treatment of acute leukemia and its effect on T-lymphocyte subsets, serum IFNgamma, IL-10 and IL-2. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005;25:303-306.
83. Cha YY, Lee EO, Lee HJ, et al. Methylene chloride fraction of Scutellaria barbata induces apoptosis in human U937 leukemia cells via the mitochondrial signaling pathway. Clin Chim Acta 2004;348:41-48.
84. Kim EK, Kwon KB, HanMJ, et al. Induction of G1 arrest and apoptosis by Scutellaria barbata in the human promyelocytic leukemia HL-60 cell line. Int J Mol Med 2007;20:123-128.
85. Kumagai T, Müller CI, Desmond JC, Imai Y, Heber D, Koeffler HP. Scutellaria baicalensis, a herbal medicine: antiproliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines. Leuk Res 2007;31:523-530.
86. Ma Z, Otsuyama K, Liu S, et al. Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. Blood 2005;105:3312-3318.
87. Liu S, Ma Z, Cai H, Li Q, Rong W, Kawano M. Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells. Eur J Haematol 2010;84:137-144.
88. Yang LL, Lee CY, Yen KY. Induction of apoptosis by hydrolyzable tannins from Eugenia jambos L. on human leukemia cells. Cancer Lett 2000;157:65-75.
89. Huang HL, Chen CC, Yeh CY, Huang RL. Reactive oxygen species mediation of baizhu-induced apoptosis in human leukemia cells. J Ethnopharmacol 2005;97:21-29.
90. Yan Q, Li Y, Jiang Z, Sun Y, Zhu L, Ding Z. Antiproliferation and apoptosis of human tumor cell lines by a lectin (AMML) of Astragalus mongholicus. Phytomedicine 2009; 16:586-593.
91. Zhu JY, Lavrik IN, Mahlknecht U, et al. The traditional Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of mitogenactivated protein kinase activities. Int J Cancer 2007;121: 1839-1846.
92. Lau CB, Ho CY, Kim CF, et al. Cytotoxic activities of Coriolus versicolor (Yunzhi) extract on human leukemia and lymphoma cells by induction of apoptosis. Life Sci 2004; 75:797-808.
93. Jiménez-Medina E, Berruguilla E, Romero I, et al. The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis. BMC Cancer 2008;8:78.
94. Perez AT, Arun B, Tripathy D, et al. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat 2010;120:111-118.